Charles Schwab Investment Management Inc. Increases Position in Organon & Co. (NYSE:OGN)

Charles Schwab Investment Management Inc. lifted its position in Organon & Co. (NYSE:OGN) by 0.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,333,703 shares of the company’s stock after buying an additional 10,652 shares during the period. Charles Schwab Investment Management Inc. owned about 1.29% of Organon & Co. worth $49,739,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Pacer Advisors Inc. increased its holdings in Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after buying an additional 11,140,388 shares during the last quarter. Weiss Asset Management LP bought a new position in Organon & Co. during the third quarter valued at $32,966,000. Jacobs Levy Equity Management Inc. boosted its stake in shares of Organon & Co. by 303.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company’s stock worth $23,762,000 after purchasing an additional 934,505 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of Organon & Co. by 191.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 760,807 shares of the company’s stock worth $11,382,000 after purchasing an additional 499,616 shares during the period. Finally, Foundry Partners LLC purchased a new stake in Organon & Co. in the 3rd quarter valued at about $7,642,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $14.97 on Friday. The firm’s fifty day simple moving average is $15.46 and its 200-day simple moving average is $16.78. The stock has a market capitalization of $3.86 billion, a price-to-earnings ratio of 4.49, a PEG ratio of 0.90 and a beta of 0.76. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. As a group, equities analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.48%. Organon & Co.’s dividend payout ratio (DPR) is 33.63%.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Barclays reduced their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Morgan Stanley dropped their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, February 14th. Finally, TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.